Company Analysis Exact Sciences Corporation
1. Summary
Advantages
- The stock's return over the last year (98.06%) is higher than the sector average (-1.82%).
Disadvantages
- Price (102.26 $) is higher than fair price (82.66 $)
- Dividends (0%) are below the sector average (0.53%).
- Current debt level 46.47% has increased over 5 years from 29.61%.
- The company's current efficiency (ROE=-37.09%) is lower than the sector average (ROE=104.24%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Exact Sciences Corporation | Healthcare | Index | |
|---|---|---|---|
| 7 days | -0.2% | -14.2% | -2.3% |
| 90 days | 1.3% | -3.6% | 0.9% |
| 1 year | 98.1% | -1.8% | 16.4% |
EXAS vs Sector: Exact Sciences Corporation has outperformed the "Healthcare" sector by 99.88% over the past year.
EXAS vs Market: Exact Sciences Corporation has outperformed the market by 81.7% over the past year.
Stable price: EXAS is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: EXAS with weekly volatility of 1.89% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (102.26 $) is higher than the fair price (82.66 $).
Price is higher than fair: The current price (102.26 $) is 19.2% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-7.47) is lower than that of the sector as a whole (36.09).
P/E vs Market: The company's P/E (-7.47) is higher than that of the market as a whole (-104.3).
5.3. P/BV
P/BV vs Sector: The company's P/BV (4.31) is lower than that of the sector as a whole (254.48).
P/BV vs Market: The company's P/BV (4.31) is lower than that of the market as a whole (72.17).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (3.75) is lower than that of the sector as a whole (127.4).
P/S vs Market: The company's P/S indicator (3.75) is lower than that of the market as a whole (114).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-15.86) is higher than that of the sector as a whole (-27.32).
EV/Ebitda vs Market: The company's EV/Ebitda (-15.86) is higher than that of the market as a whole (-78.04).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 14.55% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (14.55%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (435.8%).
6.4. ROE
ROE vs Sector: The company's ROE (-37.09%) is lower than that of the sector as a whole (104.24%).
ROE vs Market: The company's ROE (-37.09%) is lower than that of the market as a whole (-6.22%).
6.6. ROA
ROA vs Sector: The company's ROA (-16.6%) is lower than that of the sector as a whole (-2.25%).
ROA vs Market: The company's ROA (-16.6%) is lower than that of the market as a whole (38.45%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-12.57%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-12.57%) is lower than that of the market as a whole (9.79%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.53%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 19.11.2025 | ORVILLE JACOB A Officer |
Purchase | 75 | 37 500 | 5 000 |
| 24.10.2025 | Zanotti Katherine S Director |
Sale | 65 | 78 000 | 12 000 |
| 09.10.2025 | Doyle James Edward Director |
Sale | 60 | 120 000 | 2 000 |
| 09.10.2025 | Herriott James SVP, General Counsel & Sec |
Sale | 60 | 90 000 | 1 500 |
| 01.05.2024 | Conroy Kevin T President and CEO |
Sale | 60.15 | 69 473 | 1 155 |
Based on sources: porti.ru
